You are here: Industry Insights > McKesson

News List

Ontada Signs Strategic Agreement with Merck to Facilitate the Development of Data-Driven Insights to Impact Quality of Cancer Care firstwordpharma
August 27, 2021
OntadaTM, McKesson's oncology and insights business, today announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation.
New York, drug distributors reach $1.18 billion opioid settlement as national deal looms expresspharma
July 22, 2021
The three largest US drug distributors agreed mid-trial to pay up to $1.18 billion to settle claims by New York state and two of its biggest counties over their role in the nation-wide opioid epidemic, the state’s attorney general said 20th.
McKesson Corporation Enters Agreement to Sell Certain European Businesses to the PHOENIX Group firstwordpharma
July 08, 2021
McKesson Corporation (NYSE: MCK) today announced that it has entered into an agreement to sell its European businesses in France, Italy, Ireland, Portugal, Belgium, and Slovenia to the
Pharma is making steady progress toward meeting 2023 DSCSA requirements, finds study europeanpharmaceuticalreview
March 16, 2021
Over 90 percent of packages at three companies met all of the Drug Supply Chain Security Act (DSCSA) labelling requirements in 2020, despite there being three years until the final deadline.
McKesson called out by FDA's Gottlieb over opioid tampering fiercepharma
February 24, 2019
Drug distributor McKesson, which has already paid $150 million in federal penalties for lax controls over opioids in its supply chain, has now been personally lambasted by FDA Commissioner Scott Gottlieb, M.D., for newly discovered failings.
PANTHERx® Specialty Pharmacy and RxCrossroads™ by McKesson Collaborate to Simplify the Channel for Precision Medicine Therapies pharmafocusasia
November 05, 2018
PANTHERx® Specialty Pharmacy, The Rare Disease Specialty Pharmacy®, and RxCrossroads™ by McKesson, the leading commercial solutions partner
Teva kept silence for weeks on upcoming generics blow fiercepharma
August 14, 2017
Teva last week walked back 2017 sales guidance by more than $1 billion for the second time this year.